Tempest Therapeutics
TPST
73 hedge funds and large institutions have $230M invested in Tempest Therapeutics in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 14 closing their positions.
5% less capital invested
Capital invested by funds: $243M → $230M (-$12.7M)
6% less funds holding
Funds holding: 78 → 73 (-5)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
88% less call options, than puts
Call options by funds: $80K | Put options by funds: $640K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$6.07M |
| 2 |
Jennison Associates
New York
|
+$4.33M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$2.83M |
| 4 |
D.E. Shaw & Co
New York
|
+$423K |
| 5 |
Millennium Management
New York
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.15M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$2.58M |
| 3 |
Goldman Sachs
New York
|
-$2.35M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.75M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$1.62M |
TPST Hedge Fund Activity: Q1 2016 in Review
73 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2016, worth a combined $230M — down 5.2% from $243M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TPST and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was GMT Capital, opening a new position worth an estimated $6.07M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.15M sold.
- 73 institutional investors held Tempest Therapeutics (TPST) as of Q1 2016, down from 78 in Q4 2015.
- Funds reported $230M of Tempest Therapeutics stock for Q1 2016, down 5.2% quarter-over-quarter.
- 10 funds opened new Tempest Therapeutics positions in Q1 2016 and 14 closed out, a net change of -4 holders.
- The largest Tempest Therapeutics buyer in Q1 2016 was GMT Capital, an estimated $6.07M added.
- The largest Tempest Therapeutics seller in Q1 2016 was EcoR1 Capital, an estimated $4.15M sold.
Based on aggregated 13F filings for Q1 2016.